Bristol Ebitda from 2010 to 2025

BMY Stock  USD 60.42  0.34  0.57%   
Bristol Myers EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about 3 B in 2025. During the period from 2010 to 2025, Bristol Myers EBITDA regression line of annual values had r-squared of  0.22 and arithmetic mean of  7,172,287,500. View All Fundamentals
 
EBITDA  
First Reported
1987-03-31
Previous Quarter
4.8 B
Current Value
2.6 B
Quarterly Volatility
1.8 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Ebitda Growth Pattern

Below is the plot of the Ebitda of Bristol Myers Squibb over the last few years. It is Bristol Myers' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Bristol Ebitda Regression Statistics

Arithmetic Mean7,172,287,500
Geometric Mean5,260,135,594
Coefficient Of Variation89.15
Mean Deviation4,665,392,188
Median5,617,000,000
Standard Deviation6,394,252,500
Sample Variance40886465T
Range18.8B
R-Value0.47
Mean Square Error34328666.1T
R-Squared0.22
Significance0.07
Slope624,725,000
Total Sum of Squares613296975.4T

Bristol Ebitda History

2025B
20243.2 B
202319.4 B
202219.2 B
202120.2 B
2020B
20196.6 B

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA3.2 BB

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.